Vyhledat

22 Result(s)
Seřadit podle

emperor-preserved-chmp-positive-opinion

emperor-preserved-chmp-positive-opinion

CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
Jardiance®

Jardiance®

Treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
Synjardy®

Synjardy®

Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with metformin does not lead to sufficient control or when patients are treated with jardiance® (empagliflozin) and metformin.
empulse-trial-benefit-acute-heart-failure

empulse-trial-benefit-acute-heart-failure

Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
real-world-benefit-shown-in-T2D-treatment

real-world-benefit-shown-in-T2D-treatment

Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
emperor-preserved-heart-failure-full-data

emperor-preserved-heart-failure-full-data

Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
emperor-preserved-kidney-subanalysis

emperor-preserved-kidney-subanalysis

New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
Pro veřejnost

Pro veřejnost

informace o léčivých přípravcích společnosti Boehringer Ingelheim registrovaných v České republice.
Pro odborníky

Pro odborníky

Informace o léčivých přípravcích společnosti Boehringer Ingelheim registrovaných v České republice